Combined clinical and laboratory studies with carbenicillin and ticarcillin

El, Westerman; Mw, Bradshaw; Me, Ein; Nj, Smith; Tw, Williams

doi:10.1097/00000441-197809000-00003

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown carbenicillin and ticarcillin to be suitable agents for treating anaerobic infections (9,(14)(15)(16). Given the greater in vitro activity of LY127935, especially against Bacteroides spp., it may provide a useful clinical alternative.…”

Section: Discussionmentioning

confidence: 99%

Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates

Reimer¹,

Mirrett²,

Reller³

1980

Antimicrob Agents Chemother

View full text Add to dashboard Cite

To compare the in vitro activity of moxalactam (LY127935), a new broad-spectrum antimicrobial agent, with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin, each drug was tested against 420 bacterial isolates from the blood of septic patients. Standard broth dilution methods were used to determine minimum inhibitory and bactericidal concentrations. LY127935 was as active as the aminoglycosides against aerobic gram-negative organisms, including Pseudomonas aeruginosa, and was at least 10-fold more active than the other beta-lactam agents against these bacteria. LY127935 was the most active agent tested against Bacteroides fragilis; its activity against all other anaerobic bacteria and Staphylococcus aureus was similar to those of the other agents tested. All streptococci, however, grew at higher concentrations of LY127935 than any other drug, and Streptococcus faecalis and Listeria monocytogenes were not inhibited at the highest concentration tested (minimum inhibitory concentration, > 64 microgram/ml). Although a greater proportion of blood culture isolates were susceptible to LY127935 than to any other drug tested, LY127935 does not have a sufficiently broad spectrum of in vitro activity to be recommended safely alone for empirical treatment of sepsis of unknown etiology.

show abstract

Section: Discussionmentioning

confidence: 99%